Postpartum Depression Drugs Market Trends, Share, Size, Demand, Revenue and Future Outlook
Postpartum Depression Drugs Market Growth, Size, Trends Analysis- By Type, By Treatment, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
| Published: Dec-2024 | Report ID: PHAR2418 | Pages: 1 - 261 | Formats*: |
| Category : Pharmaceutical | |||
Postpartum Depression Drugs Market Introduction and Overview
According to SPER Market Research, the Global Postpartum Depression Drugs Market is estimated to reach USD 2150.99 million by 2033 with a CAGR of 9.88%.
The report includes an in-depth analysis of the Global Postpartum Depression Drugs Market, including market size and trends, product mix, Applications, and supplier analysis. Postpartum depression (PPD) is a medical illness that can arise during pregnancy or in the first year following childbirth. This medical disorder is also referred to as perinatal depression. It is related with prolonged feelings of melancholy, anxiety, and exhaustion following childbirth. Postpartum depression, which affects 10% to 15% of women worldwide, is one of the most prevalent consequences of pregnancy. This medical issue can be managed with medication and counseling.
- A new natural supplement developed, researched, manufactured, and marketed by the Centre for Addiction and Mental Health (CAMH) in April 2024 helps prevent postpartum blues and reduce symptoms of postpartum depression in the six months following childbirth.
- Zurzuvae (zuranolone), created by Sage Therapeutics, Inc., was approved by the FDA in October 2023 to treat postpartum depression in adult patients in the United States. This is the first oral medication approved by the FDA. It is anticipated that this clearance will propel market expansion.
Market Opportunities and Challenges
Opportunities:
Growing Understanding of Illness and Its Treatment to Accelerate Market Development
The symptoms of postpartum depression (PPD) have been more widely known in recent years, and more people are seeking medical help as a result of this. This has resulted in a rise in postpartum depression diagnostic rates, which in turn fuels the demand for medications used to treat the illness. The disease's rising prevalence is driving up demand for medications, which is driving market expansion. Healthcare practitioners are under more pressure to manage the patient pool as the number of individuals with this ailment rises worldwide. Treatment for postpartum depression is therefore becoming more and more necessary.
Challenges: Side effects of many PPD medications, especially antidepressants, include weight gain, nausea, exhaustion, dizziness, and sleeplessness. There may also be a lack of long-term safety data for more recent PPD medications. Patients and healthcare professionals may be cautious of utilizing these drugs due to this ambiguity until more thorough evidence is available. Therefore, the market's expansion is being impeded by the drug's adverse effects and safety concerns.The stigma associated with mental health conditions, such as postpartum depression, can deter women from getting treatment and reduce the demand for medications to treat the condition. Treatment alternatives are also accepted and used differently depending on cultural attitudes and beliefs about mental health.
Market Competitive Landscape
Local markets are competitive, and the global market is reasonably concentrated as a result of the absence of significant players. Major participants include Pfizer Inc, Sage Therapeutics, Inc, Bausch Health Companies Inc, Cipla Inc, and others.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Type, By Treatment, By End User. |
| Regions covered | North America, Asia-Pacific, Latin America, Middle East & Africa and Europe. |
| Companies Covered | Pfizer Inc, Sage Therapeutics, Inc, Bausch Health Companies Inc, Eli Lilly, Aurobindo Pharma, Lupin, Sun Pharmaceutical Industries Ltd, SHIONOGI & Co., Ltd, Cipla Inc, Teva Pharmaceutical Industries Ltd. |
COVID-19 Impact on Global Postpartum Depression Drugs Market
Pandemic-related limitations caused clinical studies for some novel medications to be postponed or stopped. Innovative treatments that could have helped patients were developed and approved more slowly as a result. The capacity of people to pay for prescription drugs and medical care was impacted by economic uncertainty during the pandemic. This financial burden made these medications even more difficult to obtain, particularly in areas with insufficient health insurance. In addition to raising treatment demand, this made it more difficult to provide efficient care and support from a distance. The market was thus negatively impacted by the COVID-19 pandemic.
By Treatment Insights
The pharmacotherapy segment had the biggest share in 2023. Pharmacotherapy is essential in the treatment of postpartum depression (PPD) since it has several significant benefits, including the potential to treat severe instances, address biological causes, and provide immediate symptom alleviation. Furthermore, advances in pharmacological treatment, such as its increased usage in conjunction with psychotherapy, such as cognitive-behavioral therapy (CBT) or interpersonal therapy (IPT), give a more comprehensive therapeutic strategy. This combination may be more beneficial than each medication alone, as it addresses both the medical and psychological elements of PPD while also encouraging segment growth.
Key Target Audience:
- Healthcare Providers
- Patients and Caregivers
- Pharmaceutical Companies
- Healthcare Institutions
- Government and Public Health Bodies
- Research and Academic Institutions
- Non-Profit Organizations and Advocacy Groups
- Retail and Distribution Channels
- Technology and Digital Health Companies
Our in-depth analysis of the Postpartum Depression Drugs Market includes the following segments:
| By Type: | |
| By Treatment: | |
| By End User: |
Key Topics Covered in the Report:
- Global Postpartum Depression Drugs Market Size (FY’2024-FY’2033)
- Overview of Global Postpartum Depression Drugs Market
- Segmentation of Global Postpartum Depression Drugs Market by Type (Postpartum Anxiety, Postpartum Post-Traumatic Stress Disorder, Postpartum Panic Disorder, Postpartum Psychosis, and Others)
- Segmentation of Global Postpartum Depression Drugs Market By Treatment (Psychotherapy, Supplements, and Others)
- Segmentation of Global Postpartum Depression Drugs Market By End User (Hospitals and Clinics, Specialty Centers, and Others)
- Statistical Snap of Global Postpartum Depression Drugs Market
- Expansion Analysis of Global Postpartum Depression Drugs Market
- Problems and Obstacles in Global Postpartum Depression Drugs Market
- Competitive Landscape in the Global Postpartum Depression Drugs Market
- Impact of COVID-19 and Demonetization on Global Postpartum Depression Drugs Market
- Details on Current Investment in Global Postpartum Depression Drugs Market
- Competitive Analysis of Global Postpartum Depression Drugs Market
- Prominent Players in the Global Postpartum Depression Drugs Market
- SWOT Analysis of Global Postpartum Depression Drugs Market
- Global Postpartum Depression Drugs Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPERs internal database2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Postpartum Depression Drugs Market.
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Postpartum Depression Drugs Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Postpartum Depression Drugs Market
7. Global Postpartum Depression Drugs Market, By Type (USD Million) 2020-2033
7.1. Global Postpartum Depression Drugs Market Size, Share and Forecast, By Type, 2020-20267.2. Global Postpartum Depression Drugs Market Size, Share and Forecast, By Type, 2027-20337.3. Postpartum Anxiety7.4. Postpartum Post-Traumatic Stress Disorder7.5. Postpartum Panic Disorder7.6. Postpartum Psychosis7.7. Others
8. Global Postpartum Depression Drugs Market, By Treatment (USD Million) 2020-2033
8.1. Global Postpartum Depression Drugs Market Size, Share and Forecast, By Treatment, 2020-20268.2. Global Postpartum Depression Drugs Market Size, Share and Forecast, By Treatment, 2027-20338.3. Psychotherapy8.4. Supplements8.5. Others
9. Global Postpartum Depression Drugs Market, By End User (USD Million) 2020-2033
9.1. Global Postpartum Depression Drugs Market Size, Share and Forecast, By End User, 2020-20269.2. Global Postpartum Depression Drugs Market Size, Share and Forecast, By End User, 2027-20339.3. Hospitals and Clinics9.4. Specialty Centers9.5. Others
10. Global Postpartum Depression Drugs Market Forecast, 2020-2033 (USD Million)
10.1. Global Postpartum Depression Drugs Market Size and Market Share
11. Global Postpartum Depression Drugs Market, By Region, 2020-2033 (USD Million)
11.1. Global Postpartum Depression Drugs Market Size and Market Share By Region (2020-2026)11.2. Global Postpartum Depression Drugs Market Size and Market Share By Region (2027-2033)11.3. Asia-Pacific
11.3.1. Australia11.3.2. China11.3.3. India11.3.4. Japan11.3.5. South Korea11.3.6. Rest of Asia-Pacific
11.4. Europe
11.4.1. France11.4.2. Germany11.4.3. Italy11.4.4. Spain11.4.5. United Kingdom11.4.6. Rest of Europe
11.5. Middle East and Africa
11.5.1. Kingdom of Saudi Arabia11.5.2. United Arab Emirates11.5.3. Qatar11.5.4. South Africa11.5.5. Egypt11.5.6. Morocco11.5.7. Nigeria11.5.8. Rest of Middle-East and Africa
11.6. North America
11.6.1. Canada11.6.2. Mexico11.6.3. United States11.7. Latin America11.7.1. Argentina11.7.2. Brazil11.7.3. Rest of Latin America
12. Company Profile
12.1. Pfizer Inc
12.1.1. Company details12.1.2. Financial outlook12.1.3. Product summary12.1.4. Recent developments
12.2. Sage Therapeutics, Inc
12.2.1. Company details12.2.2. Financial outlook12.2.3. Product summary12.2.4. Recent developments
12.3. Bausch Health Companies Inc
12.3.1. Company details12.3.2. Financial outlook12.3.3. Product summary12.3.4. Recent developments
12.4. Eli Lilly
12.4.1. Company details12.4.2. Financial outlook12.4.3. Product summary12.4.4. Recent developments
12.5. Aurobindo Pharma
12.5.1. Company details12.5.2. Financial outlook12.5.3. Product summary12.5.4. Recent developments
12.6. Lupin
12.6.1. Company details12.6.2. Financial outlook12.6.3. Product summary12.6.4. Recent developments
12.7. Sun Pharmaceutical Industries Ltd
12.7.1. Company details12.7.2. Financial outlook12.7.3. Product summary12.7.4. Recent developments
12.8. SHIONOGI & Co., Ltd
12.8.1. Company details12.8.2. Financial outlook12.8.3. Product summary12.8.4. Recent developments
12.9. Cipla Inc
12.9.1. Company details12.9.2. Financial outlook12.9.3. Product summary12.9.4. Recent developments
12.10. Teva Pharmaceutical Industries Ltd
12.10.1. Company details12.10.2. Financial outlook12.10.3. Product summary12.10.4. Recent developments
12.11. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Postpartum Depression Drugs Market is projected to reach USD 2150.99 million by 2033, growing at a CAGR of 9.88% during the forecast period.
Postpartum Depression Drugs Market grew in Market size from 2024. The Market is expected to reach USD 2150.99 million by 2033, at a CAGR of 9.88% during the forecast period.
Postpartum Depression Drugs Market CAGR of 9.88% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Postpartum Depression Drugs Market size is USD 2150.99 million from 2024 to 2033.
Postpartum Depression Drugs Market is covered By Type, By Treatment, By End User.
The North America is anticipated to have the highest Market share in the Postpartum Depression Drugs Market.
The key players in the Market include Companies Covered Pfizer Inc, Sage Therapeutics, Inc, Bausch Health Companies Inc, Eli Lilly, Aurobindo Pharma, Lupin, Sun Pharmaceutical Industries Ltd, SHIONOGI & Co., Ltd, Cipla Inc, Teva Pharmaceutical Industries Ltd.
Postpartum depression (PPD) is a medical illness that can arise during pregnancy or in the first year following childbirth. This medical disorder is also referred to as perinatal depression. It is related with prolonged feelings of melancholy, anxiety, and exhaustion following childbirth.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
